Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Robert H. Vonderheide, MD, DPhil
Advertisement
Articles by Robert H. Vonderheide, MD, DPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
2
84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study
3
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
4
Radiation Oncology Trials You May Have Missed at ASCO 2026
5